DR. ALEX KENTSIS, MD, PHD
Medical Practice at Brookline Ave, Boston, MA
License number
Massachusetts 228425
Category
Medical Practice
Type
Pediatrics
Address
Address
450 Brookline Ave, Boston, MA 02215
Phone
(617) 632-4130
(617) 632-4410 (Fax)
(617) 632-4410 (Fax)
Organization information
See more information about ALEX KENTSIS at bizstanding.comAlex Kentsis MD,PHD
300 Longwood Ave, Boston, MA 02115
Industry:
Pediatrician
Phone:
(617) 355-8241 (Phone)
Alex Kentsis
Professional information
Dr. Alex Kentsis, Boston MA - MD (Doctor of Medicine)
Specialties:
Pediatric Hematology & Oncology
Age:
50
Address:
44 Binney St, Boston 02115
(617) 632-4130 (Phone), (617) 730-4860 (Fax)
450 Brookline Ave, Boston 02215
(617) 632-4130 (Phone), (617) 632-4410 (Fax)
MEMORIAL SLOAN-KETTERIN
1275 York Ave STE 223, New York 10065
(888) 675-9875 (Phone), (800) 999-3275 (Fax)
(617) 632-4130 (Phone), (617) 730-4860 (Fax)
450 Brookline Ave, Boston 02215
(617) 632-4130 (Phone), (617) 632-4410 (Fax)
MEMORIAL SLOAN-KETTERIN
1275 York Ave STE 223, New York 10065
(888) 675-9875 (Phone), (800) 999-3275 (Fax)
Languages:
English
Education:
Medical School
Mount Sinai School of Medicine
Graduated: 2002
Children's Hospital Boston
Mount Sinai School of Medicine
Graduated: 2002
Children's Hospital Boston
Alex Kentsis, New York NY
Specialties:
Pediatrician
Address:
1275 York Ave, New York, NY 10065
450 Brookline Ave, Boston, MA 02215
450 Brookline Ave, Boston, MA 02215
Translational Dysfunction Based Therapeutics
US Patent:
2009016, Jun 25, 2009
Filed:
Jun 27, 2008
Appl. No.:
12/163449
Inventors:
Katherine L.B. Borden - St. Laurent, CA
Biljana Culjkovic - Montreal, CA
Alex Kentsis - Boston MA, US
Biljana Culjkovic - Montreal, CA
Alex Kentsis - Boston MA, US
Assignee:
Translational Therapeutics, Inc. - Arlington MA
International Classification:
A61K 31/4196, C12N 5/06
US Classification:
514383, 435375
Abstract:
Provided are methods and compositions for inhibiting eukaryotic translation initiation factor eIF4E. Such methods and compositions may be used alone or in conjunction with other therapies, such as gene therapies, for inhibiting cell proliferation and/or treating cancer.